Novartis AG to Post Q1 2025 Earnings of $1.93 Per Share, Zacks Research Forecasts (NYSE:NVS)

Novartis AG (NYSE:NVS) – Stock analysts at Zacks Research upped their Q1 2025 earnings estimates for shares of Novartis in a research note issued to investors on Monday, September 30th. Zacks Research analyst E. Bagri now expects that the company will post earnings per share of $1.93 for the quarter, up from their prior estimate of $1.92. The consensus estimate for Novartis’ current full-year earnings is $7.50 per share. Zacks Research also issued estimates for Novartis’ Q3 2025 earnings at $2.20 EPS and FY2025 earnings at $8.26 EPS.

Novartis (NYSE:NVS) last posted its earnings results on Thursday, July 18th. The company reported $1.97 EPS for the quarter, beating analysts’ consensus estimates of $1.87 by $0.10. The business had revenue of $12.87 billion for the quarter, compared to the consensus estimate of $12.24 billion. Novartis had a net margin of 33.76% and a return on equity of 34.56%. During the same quarter last year, the firm posted $1.83 EPS.

A number of other research firms have also recently weighed in on NVS. Bank of America cut shares of Novartis from a “buy” rating to a “neutral” rating and lowered their price target for the company from $135.00 to $130.00 in a report on Wednesday, September 11th. Barclays upgraded shares of Novartis to a “strong sell” rating in a research note on Monday, June 24th. The Goldman Sachs Group reissued a “neutral” rating and set a $121.00 price target (up from $119.00) on shares of Novartis in a research report on Thursday, September 5th. Jefferies Financial Group lowered shares of Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, September 3rd. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Novartis in a research report on Friday, July 19th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $120.70.

Novartis Trading Down 0.6 %

NYSE NVS opened at $113.77 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.72 and a current ratio of 0.93. The company has a market capitalization of $232.55 billion, a price-to-earnings ratio of 15.35, a price-to-earnings-growth ratio of 1.73 and a beta of 0.57. The company’s 50-day simple moving average is $115.35 and its two-hundred day simple moving average is $106.41. Novartis has a one year low of $92.19 and a one year high of $120.92.

Hedge Funds Weigh In On Novartis

Institutional investors have recently made changes to their positions in the company. Private Ocean LLC purchased a new position in shares of Novartis during the 1st quarter valued at approximately $25,000. Richardson Financial Services Inc. purchased a new position in shares of Novartis during the 4th quarter valued at approximately $26,000. New Millennium Group LLC purchased a new position in shares of Novartis during the 2nd quarter valued at approximately $28,000. Clearstead Trust LLC increased its holdings in shares of Novartis by 73.5% during the 1st quarter. Clearstead Trust LLC now owns 269 shares of the company’s stock valued at $26,000 after purchasing an additional 114 shares in the last quarter. Finally, Lynx Investment Advisory purchased a new stake in Novartis in the 2nd quarter worth $29,000. 13.12% of the stock is owned by hedge funds and other institutional investors.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.